JP2014501505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501505A5 JP2014501505A5 JP2013539992A JP2013539992A JP2014501505A5 JP 2014501505 A5 JP2014501505 A5 JP 2014501505A5 JP 2013539992 A JP2013539992 A JP 2013539992A JP 2013539992 A JP2013539992 A JP 2013539992A JP 2014501505 A5 JP2014501505 A5 JP 2014501505A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cell
- polyclonal
- population
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 179
- 238000000034 method Methods 0.000 claims description 151
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 93
- 239000013598 vector Substances 0.000 claims description 56
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 108091008874 T cell receptors Proteins 0.000 claims description 22
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 22
- 230000001177 retroviral effect Effects 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 12
- 102100034343 Integrase Human genes 0.000 claims description 12
- 108010061833 Integrases Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
- 108010084455 Zeocin Proteins 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229930189065 blasticidin Natural products 0.000 claims description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 4
- 229950010131 puromycin Drugs 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 3
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 3
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 3
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 3
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims description 3
- 239000013607 AAV vector Substances 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 238000011529 RT qPCR Methods 0.000 claims description 2
- 102000018120 Recombinases Human genes 0.000 claims description 2
- 108010091086 Recombinases Proteins 0.000 claims description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 238000002523 gelfiltration Methods 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41422510P | 2010-11-16 | 2010-11-16 | |
| US61/414,225 | 2010-11-16 | ||
| PCT/US2011/061092 WO2012068317A2 (en) | 2010-11-16 | 2011-11-16 | Methods for producing recombinant proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501505A JP2014501505A (ja) | 2014-01-23 |
| JP2014501505A5 true JP2014501505A5 (enExample) | 2015-01-08 |
| JP6092782B2 JP6092782B2 (ja) | 2017-03-08 |
Family
ID=45406837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539992A Expired - Fee Related JP6092782B2 (ja) | 2010-11-16 | 2011-11-16 | 組換えタンパク質の製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8617881B2 (enExample) |
| EP (1) | EP2640743B1 (enExample) |
| JP (1) | JP6092782B2 (enExample) |
| AU (1) | AU2011329872B2 (enExample) |
| CA (1) | CA2817751C (enExample) |
| DK (1) | DK2640743T3 (enExample) |
| WO (1) | WO2012068317A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI702955B (zh) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ） |
| WO2015142941A1 (en) | 2014-03-17 | 2015-09-24 | Avalanche Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| TWI554608B (zh) * | 2015-03-27 | 2016-10-21 | Univ China Medical | A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CA3104390A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| JP2024520790A (ja) * | 2021-06-10 | 2024-05-24 | ヤンセン バイオテツク，インコーポレーテツド | Ｋｌｋ２－ｇｐｉ融合タンパク質をコードする核酸、組換え細胞、及びその使用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| US5686120A (en) | 1995-05-22 | 1997-11-11 | Wisconsin Alumni Research Foundation | Pre-mRNA processing enhancer and method for intron-independent gene expression |
| AU737155B2 (en) | 1997-03-14 | 2001-08-09 | Biogen Idec Inc. | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| CA2379115C (en) | 1999-07-23 | 2011-04-26 | The Regents Of The University Of California | Dna recombination in eukaryotic cells by the bacteriophage phic31 recombination system |
| EP1297168A2 (en) | 2000-07-03 | 2003-04-02 | Gala Design, Inc. | Expression vectors |
| US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| KR101024443B1 (ko) * | 2003-01-07 | 2011-03-23 | 심포젠 에이/에스 | 재조합 폴리클로날 단백질의 제조 방법 |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| WO2007148971A2 (en) * | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
| PL2152872T3 (pl) * | 2007-05-25 | 2011-03-31 | Symphogen As | Sposób wytwarzania rekombinowanego białka poliklonalnego |
| AU2009240386A1 (en) * | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
-
2011
- 2011-11-16 DK DK11801886.0T patent/DK2640743T3/en active
- 2011-11-16 AU AU2011329872A patent/AU2011329872B2/en active Active
- 2011-11-16 JP JP2013539992A patent/JP6092782B2/ja not_active Expired - Fee Related
- 2011-11-16 WO PCT/US2011/061092 patent/WO2012068317A2/en not_active Ceased
- 2011-11-16 EP EP11801886.0A patent/EP2640743B1/en active Active
- 2011-11-16 CA CA2817751A patent/CA2817751C/en active Active
-
2012
- 2012-06-13 US US13/495,993 patent/US8617881B2/en active Active
-
2013
- 2013-09-26 US US14/037,833 patent/US9447174B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501505A5 (enExample) | ||
| Jian et al. | Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN. 1 | |
| Phad et al. | Clonal structure, stability and dynamics of human memory B cells and circulating plasmablasts | |
| Wolf et al. | Downstream processing of cell culture-derived virus particles | |
| JP5941616B2 (ja) | 組み換えポリクローナルタンパク質を製造する方法 | |
| Sjöberg et al. | Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling | |
| US20230134868A1 (en) | Biomagnetic microsphere and preparation method therefor and use thereof | |
| Martin et al. | Epigenetic features of HIV-induced T-cell exhaustion persist despite early antiretroviral therapy | |
| JP2011524740A5 (enExample) | ||
| JPWO2022040482A5 (enExample) | ||
| WO2019023627A1 (en) | AMPLIFICATION OF MRNA SEQUENCES ENCODING APPARIED PROTEINS | |
| Kreer et al. | Exploiting B cell receptor analyses to inform on HIV-1 vaccination strategies | |
| WO2011109726A2 (en) | Homologous multi-specific antibodies | |
| US10208290B2 (en) | Virion display array for profiling functions and interactions of human membrane proteins | |
| Moreira et al. | Implementation of novel affinity ligand for lentiviral vector purification | |
| Younis et al. | Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus | |
| Lomakin et al. | Two-dimensional high-throughput on-cell screening of immunoglobulins against broad antigen repertoires | |
| Tevelev et al. | Genetic rearrangement during site specific integration event facilitates cell line development of a bispecific molecule | |
| Curtis et al. | Beyond bulk single-chain sequencing: Getting at the whole receptor | |
| CN110878124B (zh) | Dna聚合酶的抗体片段、抗体及其应用 | |
| Leavitt et al. | Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120 | |
| Grimm et al. | Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies | |
| Liu et al. | High-throughput reformatting of phage-displayed antibody fragments to IgGs by one-step emulsion PCR | |
| Wagner et al. | Monoclonal equine IgM and IgG immunoglobulins | |
| Ratto-Kim et al. | Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E |